Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1

International Journal of Pediatric Endocrinology

Helen Alexandra Spoudeas⁴  Márta Korbonits⁵  Michael Alan Levine¹  Owase Jeelani²  Chloe Bulwer³  Hoong-Wei Gan⁴ 

[1] Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, 34th and Civic Center Boulevard, Philadelphia 19104, PA, USA;Department of Neurosurgery, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, UK;Section for Experimental & Personalized Medicine, Genetics & Genomic Medicine Programme, University College London Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK;The London Centre for Pediatric Endocrinology & Diabetes, Neuroendocrine Division, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, UK;Centre for Endocrinology, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

关键词: Survivorship;    Multiple endocrine neoplasia type 1;    Pituitary neoplasms;    Macroprolactinoma;    Familial prolactinoma;   

Others  :  1219197
DOI  :  10.1186/s13633-015-0011-5

 received in 2015-05-02, accepted in 2015-06-30,  发布年份 2015

【 摘 要 】

Background

Pediatric pituitary adenomas are rare, accounting for <3 % of all childhood intracranial tumors, the majority of which are prolactinomas. Consequently, they are often misdiagnosed as other suprasellar masses such as craniopharyngiomas in this age group. Whilst guidelines exist for the treatment of adult prolactinomas, the management of childhood presentations of these benign tumors is less clear, particularly when dopamine agonist therapy fails. Given their rarity, childhood-onset pituitary adenomas are more likely to be associated with a variety of genetic syndromes, the commonest being multiple endocrine neoplasia type 1 (MEN-1).

Case description

We present a case of an early-onset, treatment-resistant giant prolactinoma occurring in an 11-year-old peripubertal boy that was initially sensitive, but subsequently highly resistant to dopamine agonist therapy, ultimately requiring multiple surgical debulking procedures and proton beam irradiation. Our patient is now left with long-term tumor- and treatment-related neuroendocrine morbidities including blindness and panhypopituitarism. Only after multiple consultations and clinical data gained from 20-year-old medical records was a complex, intergenerationally consanguineous family history revealed, compatible with MEN-1, with a splice site mutation (c.784-9G > A) being eventually identified in intron 4 of the MEN1 gene, potentially explaining the difficulties in management of this tumor. Genetic counseling and screening has now been offered to the wider family.

Conclusions

This case emphasizes the need to consider pituitary adenomas in the differential diagnosis of all pediatric suprasellar tumors by careful endocrine assessment and measurement of at least a serum prolactin concentration. It also highlights the lack of evidence for the optimal management of pediatric drug-resistant prolactinomas. Finally, the case we describe demonstrates the importance of a detailed family history and the role of genetic testing for MEN1 and AIP mutations in all cases of pediatric pituitary adenoma.

【 授权许可】

   
2015 Gan et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27(5):485-534.
• [2]Harrington MH, Casella SJ. Pituitary tumors in childhood. Curr Opin Endocrinol Diabetes Obes. 2012; 19(1):63-67.
• [3]Steele CA, MacFarlane IA, Blair J, Cuthbertson DJ, Didi M, Mallucci C et al.. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes. Eur J Endocrinol. 2010; 163(4):515-522.
• [4]Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005; 8(1):3-6.
• [5]Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol. 1994; 41(3):359-364.
• [6]Moraes AB, Silva CM, Vieira Neto L, Gadelha MR. Giant prolactinomas: the therapeutic approach. Clin Endocrinol. 2013; 79(4):447-456.
• [7]Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al.. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(2):273-288.
• [8]Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR et al.. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9):2990-3011.
• [9]Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G et al.. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002; 87(2):457-465.
• [10]Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF et al.. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. Eur J Endocrinol. 2013; 168(4):533-541.
• [11]Turner JJ, Leotlela PD, Pannett AA, Forbes SA, Bassett JH, Harding B et al.. Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2002; 87(6):2688-2693.
• [12]Kishi M, Tsukada T, Shimizu S, Hosono K, Ohkubo T, Kosuge T et al.. A novel splicing mutation (894-9 G-A) of the MEN1 gene responsible for multiple endocrine neoplasia type 1. Cancer Lett. 1999; 142(1):105-110.
• [13]Komminoth P. A 5178-9g-A splice donor site mutation in intron 4 of the MEN1 gene causing multiple endocrine neoplasia type 1. Int J Cancer J Int du Cancer. 2000; 87(2):306-307.
• [14]Diamond FB. Pituitary adenomas in childhood: development and diagnosis. Fetal Pediatr Pathol. 2006; 25(6):339-356.
• [15]Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. 1999; 84(12):4317-4323.
• [16]Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS. Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary. 2009; 12(3):186-189.
• [17]Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F et al.. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab. 1998; 83(8):2777-2780.
• [18]Colao A, Loche S, Cappabianca P, de Divitiis E, Lombardi G. Pituitary adenomas in children and adolescents: clinical presentation, diagnosis, and therapeutic strategies. Endocrinologist. 2000; 10:314-327.
• [19]Fideleff HL, Boquete HR, Suarez MG, Azaretzky M. Prolactinoma in children and adolescents. Horm Res. 2009; 72(4):197-205.
• [20]Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012; 2012:167132.
• [21]St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol. 1996; 44(3):305-309.
• [22]Howlett TA, Wass JA, Grossman A, Plowman PN, Charlesworth M, Touzel R et al.. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol. 1989; 30(2):131-140.
• [23]Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007; 356(1):39-46.
• [24]Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP et al.. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014; 99(1):90-96.
• [25]Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol. 2009; 70(1):104-108.
• [26]Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007; 356(1):29-38.
• [27]Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G et al.. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf. 2012; 35(2):159-171.
• [28]Barlier A, Jaquet P. Quinagolide--a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol. 2006; 154(2):187-195.
• [29]Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M, Martari M et al.. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010; 78(5):457-463.
• [30]Philippon M, Morange I, Barrie M, Barlier A, Taieb D, Dufour H et al.. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Ann Endocrinol. 2012; 73(3):225-229.
• [31]Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP et al.. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol. 2012; 76(6):877-886.
• [32]Hensen J, Henig A, Fahlbusch R, Meyer M, Boehnert M, Buchfelder M. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol. 1999; 50(4):431-439.
• [33]Korbonits M, Storr H, Kumar AV. Familial pituitary adenomas - who should be tested for AIP mutations? Clin Endocrinol. 2012; 77(3):351-356.
• [34]Alband N, Korbonits M. Familial pituitary tumors. Handb Clin Neurol. 2014; 124:339-360.
• [35]de Kock L, Sabbaghian N, Plourde F, Srivastava A, Weber E, Bouron-Dal Soglio D et al.. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol. 2014; 128(1):111-122.
• [36]Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. Front Horm Res. 2013; 41:63-78.
• [37]Pinnamaneni K, Birge SJ, Avioli LV. Prolactin-secreting pituitary tumor associated with von Recklinghausen’s disease. Arch Intern Med. 1980; 140(3):397-399.